论文部分内容阅读
在改性的St?ber工艺中添加亚甲基蓝(MB,药物分子)和硅烷偶联剂A171(乙烯基三甲氧基硅烷)制备得到含MB的二氧化硅颗粒(二氧化硅-MB),并用改性的Pechini方法在其表面沉积磷酸八钙(OCP),制备得到具有核壳结构的二氧化硅-MB@OCP。A171的加入量对颗粒的物相、成分和核壳结构都有显著影响。MB的释放行为,包括释放量和单体/二聚体比例对A171添加量、壳层结构和p H值敏感。相比于二氧化硅-MB,二氧化硅-MB@OCP颗粒在磷缓冲液和模拟溶酶体缓冲液中的降解率都显著提高。
MB-containing silica particles (silica-MB) were prepared by adding methylene blue (MB, drug molecule) and silane coupling agent A171 (vinyltrimethoxysilane) to the modified Stéber process, The Pechini method was used to deposit octacalcium phosphate (OCP) on its surface to prepare silica-MB @ OCP with core-shell structure. The addition of A171 has a significant effect on the phase, composition and core-shell structure of the particles. The release behavior of MB, including the amount of release and monomer / dimer ratio, is sensitive to the amount of A171 added, the shell structure and the p H value. The degradation rate of silica-MB @ OCP particles in both phosphate buffer and mock lysosome buffer was significantly increased compared to silica-MB.